Precision Diagnostics & Medicine Market-By Type
Precision Diagnostics & Medicine Market-By Product
Precision Diagnostics & Medicine Market-By Indication
Precision Diagnostics & Medicine Market-By End-User
Precision Diagnostics & Medicine Market-By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Precision Diagnostics & Medicine Market Snapshot
Chapter 4. Global Precision Diagnostics & Medicine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Precision Diagnostics & Medicine Market Trends
4.10. Global Precision Diagnostics & Medicine Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Precision Diagnostics & Medicine Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Precision Diagnostics
5.2.1.1. Genetic Testing
5.2.1.2. DTC Testing
5.2.1.3. Other Types
5.2.2. Precision Medicine
5.2.2.1. Monoclonal Antibodies
5.2.2.2. Inhibitor Drugs
5.2.2.3. Cell & Gene Therapies
5.2.2.4. Antiviral & Anti-Retroviral Drugs
5.2.2.5. Other Products
Chapter 6. Precision Diagnostics & Medicine Market Segmentation 2: Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Precision Diagnostics
6.2.1.1. Oncology
6.2.1.2. Neurology
6.2.1.3. Immunology
6.2.1.4. Other Diagnostic Indications
6.2.2. Precision Medicine
6.2.2.1. Oncology
6.2.2.2. Rare Diseases
6.2.2.3. Infectious Diseases
6.2.2.4. Hematological Disorders
6.2.2.5. Other Medicine Indications
Chapter 7. Precision Diagnostics & Medicine Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
7.2.1. Clinical Laboratories
7.2.2. Hospitals
7.2.3. Home Care Settings
Chapter 8. Precision Diagnostics & Medicine Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. Global Precision Diagnostics & Medicine Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.2.3. North America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.2.4. North America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.3. Europe
8.3.1. Europe Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.3.3. Europe Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.3.4. Europe Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.4.3. Asia Pacific Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.4.4. Asia Pacific Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.5. Latin America
8.5.1. Latin America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.5.3. Latin America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.5.4. Latin America Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.6.3. Middle East & Africa Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.6.4. Middle East & Africa Precision Diagnostics & Medicine Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. F. Hoffmann-La Roche Ltd (Switzerland)
9.2.1.1. Business Overview
9.2.1.2. Key Offering/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Agilent Technologies, Inc. (US)
9.2.3. Thermo Fisher Scientific Inc. (US)
9.2.4. Myriad Genetics, Inc. (US)
9.2.5. Guardant Health (US)
9.2.6. Abbott (US)
9.2.7. Illumina, Inc. (US)
9.2.8. Danaher (US)
9.2.9. Exact Sciences Corporation (US)
9.2.10. Qiagen (Netherlands)
9.2.11. 23andME, INC. (US)
9.2.12. ARUP Laboratories. (US)
9.2.13. Devyser (Sweden)
9.2.14. Diasorin S.P.A. (Italy)
9.2.15. Tempus (US)
9.2.16. Pillar Biosciences Inc. (US)
9.2.17. Invivoscribe, Inc. (US)
9.2.18. NeuroCode (US)
9.2.19. C2N Diagnostics (US)
9.2.20. Trinity Biotech Plc. (Ireland)
9.2.21. Amoy Diagnostics Co., Ltd. (China)
9.2.22. Novartis AG (Switzerland)
9.2.23. Bristol-Myers Squibb Company (US)
9.2.24. Gilead Sciences, Inc (US)
9.2.25. AstraZeneca (UK)
9.2.26. AbbVie Inc. (US)
9.2.27. Eli Lilly and Company (US)
9.2.28. Pfizer Inc. (US)
9.2.29. GSK plc. (UK)
9.2.30. Sanofi (France)
9.2.31. Johnson & Johnson Services, Inc. (US)
9.2.32. Vertex Pharmaceuticals Incorporated (US)
9.2.33. Amgen Inc. (US)
9.2.34. Merck KGaA (Germany)
9.2.35. Sarepta Therapeutics, Inc. (US)
9.2.36. Merck & Co., Inc.
9.2.37. Natera, Inc.
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.